"Not So Different": How a Value-Based Pathway Led to Increased Biosimilar Use

Podcast

This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.

It's no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, with few products launched relative to those approved, low uptake of the products that are available, and formulary restrictions that sometimes favor branded biologics over biosimilar options. But given the benefits that biosimilars can provide, some physicians are taking matters into their own hands with concerted efforts to bring these products to the clinic. This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.

Read more about the value-based pathway here, and find the Articularis Rheumatology Network here.

Related Videos
Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Related Content
© 2024 MJH Life Sciences

All rights reserved.